Publication | Open Access
Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides
161
Citations
24
References
2014
Year
Molecular BiologyCell DeathGlucocorticoid ReceptorNucleic Acid BiomarkersToxicological MechanismOxidative StressNucleic Acid ChemistryToxicologyHepatotoxicityAntisense TherapyAllergyLocked NucleicLiver PhysiologyLna-modified AsosOligonucleotideAntisense OligonucleotidesExperimental ToxicologyPharmacologyDrug-induced Liver InjuryBiomolecular EngineeringNatural SciencesSequence MotifsNucleic Acid BiochemistryMedicineNucleic AcidsDrug DiscoveryToxicogenomics
Fully phosphorothioate antisense oligonucleotides (ASOs) with locked nucleic acids (LNAs) improve target affinity, RNase H activation and stability. LNA modified ASOs can cause hepatotoxicity, and this risk is currently not fully understood. In vitro cytotoxicity screens have not been reliable predictors of hepatic toxicity in non-clinical testing; however, mice are considered to be a sensitive test species. To better understand the relationship between nucleotide sequence and hepatotoxicity, a structure-toxicity analysis was performed using results from 2 week repeated-dose-tolerability studies in mice administered LNA-modified ASOs. ASOs targeting human Apolipoprotien C3 (Apoc3), CREB (cAMP Response Element Binding Protein) Regulated Transcription Coactivator 2 (Crtc2) or Glucocorticoid Receptor (GR, NR3C1) were classified based upon the presence or absence of hepatotoxicity in mice. From these data, a random-decision forest-classification model generated from nucleotide sequence descriptors identified two trinucleotide motifs (TCC and TGC) that were present only in hepatotoxic sequences. We found that motif containing sequences were more likely to bind to hepatocellular proteins in vitro and increased P53 and NRF2 stress pathway activity in vivo. These results suggest in silico approaches can be utilized to establish structure-toxicity relationships of LNA-modified ASOs and decrease the likelihood of hepatotoxicity in preclinical testing.
| Year | Citations | |
|---|---|---|
Page 1
Page 1